CN112472758A - Acid-reducing tea for relieving gout and preparation method thereof - Google Patents
Acid-reducing tea for relieving gout and preparation method thereof Download PDFInfo
- Publication number
- CN112472758A CN112472758A CN202011598156.6A CN202011598156A CN112472758A CN 112472758 A CN112472758 A CN 112472758A CN 202011598156 A CN202011598156 A CN 202011598156A CN 112472758 A CN112472758 A CN 112472758A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- superfine powder
- acid
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000005569 Gout Diseases 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241001122767 Theaceae Species 0.000 title description 34
- 239000000284 extract Substances 0.000 claims abstract description 88
- 239000000843 powder Substances 0.000 claims abstract description 80
- 150000004676 glycans Chemical class 0.000 claims abstract description 38
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 38
- 239000005017 polysaccharide Substances 0.000 claims abstract description 38
- 240000004274 Sarcandra glabra Species 0.000 claims abstract description 22
- 235000010842 Sarcandra glabra Nutrition 0.000 claims abstract description 22
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 18
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 18
- 235000006484 Paeonia officinalis Nutrition 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 18
- 241000427159 Achyranthes Species 0.000 claims abstract description 8
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 8
- 241001071795 Gentiana Species 0.000 claims abstract description 8
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 8
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 8
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 8
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 8
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 8
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 8
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 8
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims abstract description 8
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims abstract description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 8
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 3
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 3
- 239000011734 sodium Substances 0.000 claims abstract description 3
- 244000269722 Thea sinensis Species 0.000 claims abstract 11
- 244000170916 Paeonia officinalis Species 0.000 claims abstract 5
- 244000111489 Gardenia augusta Species 0.000 claims abstract 3
- 240000002045 Guettarda speciosa Species 0.000 claims abstract 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 57
- 238000002156 mixing Methods 0.000 claims description 30
- 238000007873 sieving Methods 0.000 claims description 19
- 239000000463 material Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 239000006228 supernatant Substances 0.000 claims description 15
- 235000003805 Musa ABB Group Nutrition 0.000 claims description 10
- 240000008790 Musa x paradisiaca Species 0.000 claims description 10
- 235000015266 Plantago major Nutrition 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 10
- 238000005303 weighing Methods 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 229920002472 Starch Polymers 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- DBPRUZCKPFOVDV-UHFFFAOYSA-N Clorprenaline hydrochloride Chemical compound O.Cl.CC(C)NCC(O)C1=CC=CC=C1Cl DBPRUZCKPFOVDV-UHFFFAOYSA-N 0.000 claims description 5
- 241001184986 Pseudopterogorgia Species 0.000 claims description 5
- 241000512743 Sarcophyton <anthozoan> Species 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000005238 degreasing Methods 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 239000003208 petroleum Substances 0.000 claims description 5
- 230000001376 precipitating effect Effects 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000002791 soaking Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 241000589636 Xanthomonas campestris Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 239000002253 acid Substances 0.000 abstract description 6
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 5
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 208000005392 Spasm Diseases 0.000 abstract description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 2
- 230000017531 blood circulation Effects 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 2
- 229940116269 uric acid Drugs 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract 2
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 241001106477 Paeoniaceae Species 0.000 description 13
- 235000013305 food Nutrition 0.000 description 6
- 206010067484 Adverse reaction Diseases 0.000 description 5
- 244000061520 Angelica archangelica Species 0.000 description 5
- 240000001972 Gardenia jasminoides Species 0.000 description 5
- 230000006838 adverse reaction Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000008407 joint function Effects 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 201000001431 Hyperuricemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Food Science & Technology (AREA)
- Pain & Pain Management (AREA)
- Sustainable Development (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a deacidification tea for relieving gout and a preparation method thereof, wherein the raw materials comprise: 2-6 parts of sarcandra glabra polysaccharide, 1-6 parts of peach kernel superfine powder, 0.5-2 parts of safflower superfine powder, 0.5-5 parts of angelica extract, 0.5-3 parts of radix rehmanniae extract, 1-3 parts of achyranthes root extract, 1-5 parts of ligusticum wallichii extract, 1-5 parts of platycodon grandiflorum superfine powder, 1-5 parts of red paeony root superfine powder, 0.5-3 parts of fructus aurantii extract, 1-5 parts of liquorice extract, 1-5 parts of radix bupleuri extract, 0.5-5 parts of gentian extract, 0.5-5 parts of scutellaria baicalensis extract, 0.5-6 parts of gardenia extract, 0.5-3 parts of rhizoma alismatis extract, 1-2 parts of radix bupleuri extract, 0.5-3 parts of semen plantaginis superfine powder, 1-5 parts of xylo oligosaccharide, 0.02-0.5 part of dipotassium hydrogen phosphate and 0.05-0.2 part of sodium. The acid-reducing tea for relieving gout is safe to eat, free of toxic and side effects, capable of regulating qi and blood, promoting blood circulation to remove blood stasis, relieving spasm and dispelling wind, inducing diuresis to alleviate pain, expelling wind and reducing acid, promoting discharge of uric acid, capable of effectively relieving gout, simple and easy to operate, strong in reproducibility, and beneficial to large-scale production.
Description
Technical Field
The invention belongs to the field of acid-reducing tea, and particularly relates to acid-reducing tea for relieving gout and a preparation method thereof.
Background
Gout is a common and complex type of arthritis, which can be suffered by all ages, with higher incidence in men than women. Patients with gout often have sudden joint pain at night, the joint is in urgent attack, severe pain, edema, red swelling and inflammation appear at the joint, and the pain is slowly relieved until the pain disappears for days or weeks. Hyperuricemia is the basis of gout, and hyperuricemia are over-saturated in urine, so that urate is deposited in the renal tubule lumen or interstitium, and an acute inflammatory reaction is caused. At present, medicines for relieving gout mainly comprise nonsteroidal anti-inflammatory drugs and glucocorticoids, but the existing medicine relieving method is less in use, people prefer to adopt diet therapy, the diet therapy has no side effect, both symptoms and root causes are treated, diet is controlled, foods with rich purine content are strictly limited, and high-purine foods and high-fat foods, such as meat, wild flavor, seafood, yeast-containing foods and beverages, are reduced; eating food with low purine content, such as rice, wheat, starch, sorghum, egg, pig blood, duck blood, etc., as far as possible; at the same time, the health care wine can reduce weight, control weight and properly increase physical activity. In view of this, this patent is filed.
Disclosure of Invention
In order to solve the problems in the prior art, the invention provides an acid-reducing tea for relieving gout and a preparation method thereof. The acid-reducing tea for relieving gout is safe to eat, has no toxic or side effect, has the mutual cooperation of the raw materials, and has a good effect of relieving gout.
The invention aims to provide the acid-reducing tea for relieving gout. The invention also aims to provide two preparation methods of the acid-reducing tea for relieving gout. The acid-reducing tea is prepared from the following raw materials: 2-6 parts of sarcandra glabra polysaccharide, 1-6 parts of peach kernel superfine powder, 0.5-2 parts of safflower superfine powder, 0.5-5 parts of angelica extract, 0.5-3 parts of radix rehmanniae extract, 1-3 parts of achyranthes root extract, 1-5 parts of ligusticum wallichii extract, 1-5 parts of platycodon grandiflorum superfine powder, 1-5 parts of red paeony root superfine powder, 0.5-3 parts of fructus aurantii extract, 1-5 parts of liquorice extract, 1-5 parts of radix bupleuri extract, 0.5-5 parts of gentian extract, 0.5-5 parts of scutellaria baicalensis extract, 0.5-6 parts of gardenia extract, 0.5-3 parts of rhizoma alismatis extract, 1-2 parts of radix bupleuri extract, 0.5-3 parts of semen plantaginis superfine powder, 1-5 parts of xylo oligosaccharide, 0.02-0.5 part of dipotassium hydrogen phosphate and 0.05-0.2 part of sodium.
Further, the raw materials comprise the following components in parts by weight: 5 parts of sarcandra glabra polysaccharide, 4 parts of peach kernel superfine powder, 1 part of safflower superfine powder, 3 parts of angelica extract, 2 parts of radix rehmanniae extract, 2 parts of achyranthes extract, 3 parts of ligusticum wallichii extract, 3 parts of platycodon grandiflorum superfine powder, 3 parts of red paeony root superfine powder, 2 parts of fructus aurantii extract, 3 parts of liquorice extract, 3 parts of radix bupleuri extract, 3 parts of gentian extract, 3 parts of scutellaria baicalensis extract, 3 parts of gardenia extract, 2 parts of rhizoma alismatis extract, 1.5 parts of radix bupleuri extract, 1.5 parts of semen plantaginis superfine powder, 3 parts of xylo-oligosaccharide, 0.3 part of dipotassium hydrogen phosphate and 0.1 part of.
Further, the sarcandra glabra polysaccharide is prepared by the following method: pulverizing and sieving Sarcophyton xanthina, degreasing with ethyl acetate and petroleum ether respectively, adding into distilled water at a weight ratio of 1:20-30, adjusting pH to 4.5-5.5, and extracting in 85-95 deg.C water bath for 3-5 hr; taking the supernatant, cooling, carrying out enzymolysis to remove starch, and then centrifuging to obtain the supernatant; concentrating the supernatant, adding 95% diethyl ether 2-4 times the volume of the concentrated solution, precipitating overnight to obtain precipitate, and vacuum freeze drying the precipitate to obtain crude polysaccharide of Pseudopterogorgia fusca; dissolving in water to obtain solution, deproteinizing, decolorizing, dialyzing, and performing ion exchange column chromatography to obtain Xanthocorallinum hancockianum pure polysaccharide, and vacuum freeze drying to obtain Xanthocorallinum hancockianum polysaccharide.
Further, the preparation method of the acid-reducing tea for relieving gout is characterized by comprising the following steps: weighing the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder in proportion, mixing, and uniformly mixing to form mixed fine materials; (2) respectively crushing and mixing the other raw materials except the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder, uniformly mixing to form a material to be extracted, soaking the material to be extracted for 6-18 hours by using 60-90% of diethyl ether as a solvent, filtering, collecting filtrate, recovering diethyl ether, and concentrating into paste to form paste liquid; and (3) drying the paste obtained in the step (2) in vacuum, crushing, mixing with the mixed fine powder obtained in the step (1), uniformly mixing, and sieving to obtain the deacidification tea for relieving gout. Further, in the step (2), the crushing is carried out by adopting a wall breaking machine. Further, in the step (2), the fineness of the crushed particles is 100 meshes.
Further, in the step (3), the sieving is 400-mesh sieving.
Further, sterilizing the acid reducing tea for relieving gout, granulating into granules or powder by adopting a granulator, weighing and packaging to form the tea bag.
The invention has the beneficial effects that:
1. the acid-reducing tea for relieving gout disclosed by the invention adopts natural traditional Chinese medicinal materials and food materials, and retains bioactive components in the raw materials to the greatest extent through advanced processes such as strict screening, ether extraction, vacuum concentration, low-temperature drying and the like, so that the biological active components are reasonably matched, the absorption is effectively promoted, and the health-care effect of relieving gout is achieved;
2. the acid-reducing tea for relieving gout is safe to eat, has no toxic or side effect, regulates qi and blood, promotes blood circulation to remove blood stasis, relieves spasm, dispels wind, promotes diuresis, relieves pain, dispels wind, reduces acid, promotes discharge of uric acid, and can effectively relieve gout;
3. the preparation method of the acid-reducing tea for relieving gout is simple and easy to operate, has strong reproducibility and is beneficial to large-scale production.
Detailed description of the preferred embodiments
Example 1
The embodiment provides an acid-reducing tea for relieving gout, which is prepared from the following raw materials: the acid-reducing tea is prepared from the following raw materials: 2 parts of sarcandra glabra polysaccharide, 1 part of peach kernel superfine powder, 0.5 part of safflower superfine powder, 0.5 part of angelica extract, 0.5 part of radix rehmanniae extract, 1 part of achyranthes extract, 1 part of ligusticum wallichii extract, 1 part of platycodon grandiflorum superfine powder, 1 part of red paeony root superfine powder, 0.5 part of fructus aurantii extract, 1 part of liquorice extract, 1 part of radix bupleuri extract, 0.5 part of gentian extract, 0.5 part of scutellaria baicalensis extract, 0.5 part of gardenia extract, 0.5 part of rhizoma alismatis extract, 1 part of radix bupleuri extract, 0.5 part of semen plantaginis superfine powder, 1 part of xylo-oligosaccharide, 0.02 part of dipotassium hydrogen phosphate and 0.05 part of. The sarcandra glabra polysaccharide is prepared by the following method: pulverizing and sieving Sarcophyton xanthina, degreasing with ethyl acetate and petroleum ether respectively, adding into distilled water at a weight ratio of 1:20-30, adjusting pH to 4.5-5.5, and extracting in 85-95 deg.C water bath for 3-5 hr; taking the supernatant, cooling, carrying out enzymolysis to remove starch, and then centrifuging to obtain the supernatant; concentrating the supernatant, adding 95% diethyl ether 2-4 times the volume of the concentrated solution, precipitating overnight to obtain precipitate, and vacuum freeze drying the precipitate to obtain crude polysaccharide of Pseudopterogorgia fusca; dissolving in water to obtain solution, deproteinizing, decolorizing, dialyzing, and performing ion exchange column chromatography to obtain Xanthocorallinum hancockianum pure polysaccharide, and vacuum freeze drying to obtain Xanthocorallinum hancockianum polysaccharide. The preparation method of the acid-reducing tea for relieving gout is characterized by comprising the following steps: weighing the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder in proportion, mixing, and uniformly mixing to form mixed fine materials; (2) respectively crushing and mixing the other raw materials except the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder, uniformly mixing to form a material to be extracted, soaking the material to be extracted for 6-18 hours by using 60-90% of diethyl ether as a solvent, filtering, collecting filtrate, recovering diethyl ether, and concentrating into paste to form paste liquid; and (3) drying the paste obtained in the step (2) in vacuum, crushing, mixing with the mixed fine powder obtained in the step (1), uniformly mixing, and sieving to obtain the deacidification tea for relieving gout. In the step (2), the fineness of the crushed particles is 100 meshes. In the step (3), the sieving is 400-mesh sieving. Sterilizing the acid reducing tea for relieving gout, granulating into granules or powder by adopting a granulator, weighing and packaging to form the tea bag.
Example 2
The embodiment provides an acid-reducing tea for relieving gout, which is prepared from the following raw materials: the raw materials comprise the following components in parts by weight: 5 parts of sarcandra glabra polysaccharide, 4 parts of peach kernel superfine powder, 1 part of safflower superfine powder, 3 parts of angelica extract, 2 parts of radix rehmanniae extract, 2 parts of achyranthes extract, 3 parts of ligusticum wallichii extract, 3 parts of platycodon grandiflorum superfine powder, 3 parts of red paeony root superfine powder, 2 parts of fructus aurantii extract, 3 parts of liquorice extract, 3 parts of radix bupleuri extract, 3 parts of gentian extract, 3 parts of scutellaria baicalensis extract, 3 parts of gardenia extract, 2 parts of rhizoma alismatis extract, 1.5 parts of radix bupleuri extract, 1.5 parts of semen plantaginis superfine powder, 3 parts of xylo-oligosaccharide, 0.3 part of dipotassium hydrogen phosphate and 0.1 part of. The sarcandra glabra polysaccharide is prepared by the following method: pulverizing and sieving Sarcophyton xanthina, degreasing with ethyl acetate and petroleum ether respectively, adding into distilled water at a weight ratio of 1:20-30, adjusting pH to 4.5-5.5, and extracting in 85-95 deg.C water bath for 3-5 hr; taking the supernatant, cooling, carrying out enzymolysis to remove starch, and then centrifuging to obtain the supernatant; concentrating the supernatant, adding 95% diethyl ether 2-4 times the volume of the concentrated solution, precipitating overnight to obtain precipitate, and vacuum freeze drying the precipitate to obtain crude polysaccharide of Pseudopterogorgia fusca; dissolving in water to obtain solution, deproteinizing, decolorizing, dialyzing, and performing ion exchange column chromatography to obtain Xanthocorallinum hancockianum pure polysaccharide, and vacuum freeze drying to obtain Xanthocorallinum hancockianum polysaccharide. The preparation method of the acid-reducing tea for relieving gout is characterized by comprising the following steps: weighing the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder in proportion, mixing, and uniformly mixing to form mixed fine materials; (2) respectively crushing and mixing the other raw materials except the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder, uniformly mixing to form a material to be extracted, soaking the material to be extracted for 6-18 hours by using 60-90% of diethyl ether as a solvent, filtering, collecting filtrate, recovering diethyl ether, and concentrating into paste to form paste liquid; and (3) drying the paste obtained in the step (2) in vacuum, crushing, mixing with the mixed fine powder obtained in the step (1), uniformly mixing, and sieving to obtain the deacidification tea for relieving gout. In the step (2), the crushing is carried out by adopting a wall breaking machine, and the fineness of the crushed particles is 100 meshes. In the step (3), the sieving is 400-mesh sieving. Sterilizing the acid reducing tea for relieving gout, granulating into granules or powder by adopting a granulator, weighing and packaging to form the tea bag.
Example 3
The embodiment provides an acid-reducing tea for relieving gout, which is prepared from the following raw materials: the invention also aims to provide two preparation methods of the acid-reducing tea for relieving gout. The acid-reducing tea is prepared from the following raw materials: 6 parts of sarcandra glabra polysaccharide, 6 parts of peach kernel superfine powder, 2 parts of safflower superfine powder, 5 parts of angelica extract, 3 parts of radix rehmanniae extract, 3 parts of achyranthes extract, 5 parts of ligusticum wallichii extract, 5 parts of platycodon grandiflorum superfine powder, 5 parts of red paeony root superfine powder, 3 parts of fructus aurantii extract, 5 parts of liquorice extract, 5 parts of radix bupleuri extract, 5 parts of gentian extract, 5 parts of scutellaria baicalensis extract, 6 parts of gardenia extract, 3 parts of rhizoma alismatis extract, 2 parts of radix bupleuri extract, 3 parts of semen plantaginis superfine powder, 5 parts of xylo-oligosaccharide, 0.5 part of dipotassium hydrogen phosphate and 0.2 part of. The sarcandra glabra polysaccharide is prepared by the following method: pulverizing and sieving Sarcophyton xanthina, degreasing with ethyl acetate and petroleum ether respectively, adding into distilled water at a weight ratio of 1:20-30, adjusting pH to 4.5-5.5, and extracting in 85-95 deg.C water bath for 3-5 hr; taking the supernatant, cooling, carrying out enzymolysis to remove starch, and then centrifuging to obtain the supernatant; concentrating the supernatant, adding 95% diethyl ether 2-4 times the volume of the concentrated solution, precipitating overnight to obtain precipitate, and vacuum freeze drying the precipitate to obtain crude polysaccharide of Pseudopterogorgia fusca; dissolving in water to obtain solution, deproteinizing, decolorizing, dialyzing, and performing ion exchange column chromatography to obtain Xanthocorallinum hancockianum pure polysaccharide, and vacuum freeze drying to obtain Xanthocorallinum hancockianum polysaccharide. The preparation method of the acid-reducing tea for relieving gout comprises the following steps: weighing the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder in proportion, mixing, and uniformly mixing to form mixed fine materials; (2) respectively crushing and mixing the other raw materials except the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder, uniformly mixing to form a material to be extracted, soaking the material to be extracted for 6-18 hours by using 60-90% of diethyl ether as a solvent, filtering, collecting filtrate, recovering diethyl ether, and concentrating into paste to form paste liquid; and (3) drying the paste obtained in the step (2) in vacuum, crushing, mixing with the mixed fine powder obtained in the step (1), uniformly mixing, and sieving to obtain the deacidification tea for relieving gout. And (3) crushing by using a wall breaking machine in the step (2), wherein the fineness of the crushed particles is 100 meshes in the step (2). In the step (3), the sieving is 400-mesh sieving. Sterilizing the acid reducing tea for relieving gout, granulating into granules or powder by adopting a granulator, weighing and packaging to form the tea bag.
And (3) clinical trials:
1.1 clinical data 240 gout patients admitted to the traditional Chinese medicine hospital in Hubei province in 2018, 1 month-2019, were selected as observation targets and randomly divided into an observation group and a control group, wherein 120 gout patients in each group were 36-56 years old.
1.2 methods the control group used oral indomethacin enteric coated tablets of 30mg, 3 times daily. The observation group was then relieved with the powder composition of example two: the medicine is dissolved in about 300mL of boiled water and is taken orally 3 times, 2 weeks is a treatment course, and 6 treatment courses are relieved.
1.3 observing the clinical curative effect and adverse reaction occurrence of two groups of patients by observing indexes. Clinical ineffectiveness: the clinical symptoms of the patients and the knee joint function have no obvious change; the clinical effect is shown: the clinical symptoms of the patient completely disappear, and the knee joint function returns to normal; the clinical effect is as follows: the clinical symptoms of the patients are effectively controlled, and the knee joint function is improved by more than or equal to 50 percent compared with that before the relief.
1.4 statistical analysis was performed using SPSS16.0 statistical software.
2 results
2.1 clinical efficacy observed groups of two groups of patients had significantly better clinical efficacy than the control group (P < 0.05), as shown in Table 1.
TABLE 1 clinical efficacy of two groups of patients [ n (%) ]
| Group of | Show effect | Is effective | Invalidation | Effective rate of treatment |
| Observation group (120) | 45 | 46 | 9 | 91.0 |
| Control group (120) | 30 | 47 | 23 | 77 |
| X2 | 6.523 | 6.554 | 11.636 | 11.714 |
| P value | 0.000 | 0.000 | 0.000 | 0.000 |
Adverse reaction incidence rates of the two groups of patients the adverse reaction incidence rate of the observed group was significantly lower than that of the control group (P < 0.05), as shown in Table 2.
TABLE 2 incidence of adverse reactions in two groups of patients
| Group of | Allergy (S) | Nausea | Diarrhea (diarrhea) | Effective rate of treatment |
| Observation group (120) | 0 | 2 | 0 | 1.6 |
| Control group (120) | 4 | 6 | 4 | 11.6 |
| X2 | 1.691 | 3.601 | 2.714 | 7.308 |
| P value | 0.147 | 0.402 | 0.328 | 0.000 |
In the research and observation, the clinical curative effect and the adverse reaction incidence rate of an observation group are obviously superior to those of a control group (P is less than 0.05), which shows that the composition for relieving gout has better curative effect and safety in clinical relief, and is worthy of popularization and use in clinic.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.
Claims (7)
1. The acid-reducing tea for relieving gout is prepared from the following raw materials: 2-6 parts of sarcandra glabra polysaccharide, 1-6 parts of peach kernel superfine powder, 0.5-2 parts of safflower superfine powder, 0.5-5 parts of angelica extract, 0.5-3 parts of radix rehmanniae extract, 1-3 parts of achyranthes root extract, 1-5 parts of ligusticum wallichii extract, 1-5 parts of platycodon grandiflorum superfine powder, 1-5 parts of red paeony root superfine powder, 0.5-3 parts of fructus aurantii extract, 1-5 parts of liquorice extract, 1-5 parts of radix bupleuri extract, 0.5-5 parts of gentian extract, 0.5-5 parts of scutellaria baicalensis extract, 0.5-6 parts of gardenia extract, 0.5-3 parts of rhizoma alismatis extract, 1-2 parts of radix bupleuri extract, 0.5-3 parts of semen plantaginis superfine powder, 1-5 parts of xylo oligosaccharide, 0.02-0.5 part of dipotassium hydrogen phosphate and 0.05-0.2 part of sodium.
2. The acid-reducing tea for relieving gout as claimed in claim 1, wherein the acid-reducing tea is prepared from the following raw materials in parts by weight: 5 parts of sarcandra glabra polysaccharide, 4 parts of peach kernel superfine powder, 1 part of safflower superfine powder, 3 parts of angelica extract, 2 parts of radix rehmanniae extract, 2 parts of achyranthes extract, 3 parts of ligusticum wallichii extract, 3 parts of platycodon grandiflorum superfine powder, 3 parts of red paeony root superfine powder, 2 parts of fructus aurantii extract, 3 parts of liquorice extract, 3 parts of radix bupleuri extract, 3 parts of gentian extract, 3 parts of scutellaria baicalensis extract, 3 parts of gardenia extract, 2 parts of rhizoma alismatis extract, 1.5 parts of radix bupleuri extract, 1.5 parts of semen plantaginis superfine powder, 3 parts of xylo-oligosaccharide, 0.3 part of dipotassium hydrogen phosphate and 0.1 part of.
3. The acid-reducing tea for relieving gout as claimed in claims 1-2, wherein the Xanthomonas campestris polysaccharide is prepared by the following method: pulverizing and sieving Sarcophyton xanthina, degreasing with ethyl acetate and petroleum ether respectively, adding into distilled water at a weight ratio of 1:20-30, adjusting pH to 4.5-5.5, and extracting in 85-95 deg.C water bath for 3-5 hr; taking the supernatant, cooling, carrying out enzymolysis to remove starch, and then centrifuging to obtain the supernatant; concentrating the supernatant, adding 95% diethyl ether 2-4 times the volume of the concentrated solution, precipitating overnight to obtain precipitate, and vacuum freeze drying the precipitate to obtain crude polysaccharide of Pseudopterogorgia fusca; dissolving in water to obtain solution, deproteinizing, decolorizing, dialyzing, and performing ion exchange column chromatography to obtain Xanthocorallinum hancockianum pure polysaccharide, and vacuum freeze drying to obtain Xanthocorallinum hancockianum polysaccharide.
4. The preparation method of the acid-reducing tea for relieving gout as claimed in any one of claims 1 to 3, which comprises the following steps: weighing the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder in proportion, mixing, and uniformly mixing to form mixed fine materials; (2) respectively crushing and mixing the other raw materials except the sarcandra glabra polysaccharide, the safflower superfine powder, the red paeony root superfine powder and the plantain seed superfine powder, uniformly mixing to form a material to be extracted, soaking the material to be extracted for 6-18 hours by using 60-90% of diethyl ether as a solvent, filtering, collecting filtrate, recovering diethyl ether, and concentrating into paste to form paste liquid; and (3) drying the paste obtained in the step (2) in vacuum, crushing, mixing with the mixed fine powder obtained in the step (1), uniformly mixing, and sieving to obtain the deacidification tea for relieving gout.
5. The preparation method of the acid-reducing tea for relieving gout as claimed in claim 4, wherein in the step (2), the crushing is carried out by a wall breaking machine.
6. The preparation method of the acid-reducing tea for relieving gout as claimed in claim 4, wherein in the step (2), the particle fineness after the crushing is 100 meshes.
7. The preparation method of the acid-reducing tea for relieving gout as claimed in claim 4, wherein in the step (3), the sieving is performed by a 400-mesh sieve.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011598156.6A CN112472758A (en) | 2020-12-29 | 2020-12-29 | Acid-reducing tea for relieving gout and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011598156.6A CN112472758A (en) | 2020-12-29 | 2020-12-29 | Acid-reducing tea for relieving gout and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112472758A true CN112472758A (en) | 2021-03-12 |
Family
ID=74915866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011598156.6A Pending CN112472758A (en) | 2020-12-29 | 2020-12-29 | Acid-reducing tea for relieving gout and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112472758A (en) |
-
2020
- 2020-12-29 CN CN202011598156.6A patent/CN112472758A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109820943B (en) | Zhuang medicine preparation for treating gout and preparation method thereof | |
| CN105597013A (en) | Method for preparing traditional Chinese medicine composition for treating post-cholecystectomy syndrome | |
| CN114869953B (en) | Composition for resisting fatigue and enhancing immunity and treating rheumatism and preparation method thereof | |
| CN114747766A (en) | Health-care food composition capable of reducing uric acid and preparation method and application thereof | |
| CN108815339A (en) | The Chinese medicine composition and preparation for treating urarthritis and/or hyperuricemia | |
| CN112472758A (en) | Acid-reducing tea for relieving gout and preparation method thereof | |
| CN114404517A (en) | Composition for gout and reducing uric acid and application and preparation method thereof | |
| CN111068043B (en) | Composition rich in chicory and inulin, preparation method thereof and preparation for preventing gout | |
| CN112516262A (en) | Acid-reducing tea for relieving gout and preparation method thereof | |
| CN112546085A (en) | Sambucus chinensis extract for treating gout and preparation method thereof | |
| CN102335276B (en) | Preparation method and application of tree peony extract and composition of tree peony extract | |
| CN110946950A (en) | A Chinese medicinal composition for treating senile vascular dementia, and its preparation method | |
| CN103599419B (en) | Traditional Chinese medicine combination for treating gout | |
| CN103961551A (en) | Traditional Tibetan medicine for treating diabetes | |
| CN115531471B (en) | Composition for resisting African swine fever as well as preparation method and application thereof | |
| CN107875269B (en) | A Chinese medicinal composition for treating gynecological inflammation, and its preparation method | |
| CN106943554A (en) | A kind of Chinese medicine composition for being used to treat chordapsus | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN113288979A (en) | Composition for reducing uric acid and relieving gout | |
| CN105106540A (en) | Medicinal preparation for treating cerebral thrombosis | |
| CN113812613A (en) | Uric acid resistant functional food and preparation process thereof | |
| CN105106764A (en) | Medicinal preparation for treating vomitus gravidarum | |
| CN113398212A (en) | Composition for relieving gout and preparation method and application thereof | |
| CN117752711A (en) | Composition for reducing hyperuricemia as well as preparation method and application thereof | |
| CN116803406A (en) | Compound plant extract formula for reducing uric acid and pain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210312 |